colforsin has been researched along with arsenic trioxide in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Boles, E; Jiang, X; Landfear, SM; Liu, Z; Rosen, BP; Sanchez, MA | 1 |
| Mousavizadeh, K; Noori, S; Pourfathollah, A; Safa, M; Zand, H | 1 |
2 other study(ies) available for colforsin and arsenic trioxide
| Article | Year |
|---|---|
Mammalian glucose permease GLUT1 facilitates transport of arsenic trioxide and methylarsonous acid.
Topics: Animals; Arsenic Trioxide; Arsenicals; Biological Transport, Active; Cloning, Molecular; Colforsin; Cytochalasin B; Female; Glucose Transport Proteins, Facilitative; Glucose Transporter Type 1; Hexoses; Humans; In Vitro Techniques; Monosaccharide Transport Proteins; Oocytes; Oxides; Rats; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Xenopus laevis | 2006 |
cAMP protects acute promyelocytic leukemia cells from arsenic trioxide-induced caspase-3 activation and apoptosis.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; bcl-Associated Death Protein; Caspase 3; Cell Line, Tumor; Cell Proliferation; Colforsin; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; DNA; G1 Phase Cell Cycle Checkpoints; Humans; Leukemia, Promyelocytic, Acute; Oxides; Proto-Oncogene Mas; Tumor Suppressor Protein p53 | 2014 |